AsierisPharma

Asieris Pharmaceuticals is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases.

[AsierisPharma @asierispharma]

Asieris and the Obstetrics & Gynecology Hospital of Fudan University have signed a strategic cooperation agreement to advance innovation in cervical lesions & HPV-related disease.

https://t.co/fIiQeIleLp

#WomensHealth #HPV

[AsierisPharma @asierispharma]

Why do clinicians need non-surgical, tissue-preserving tools for cervical HSIL & CIN2/3? Prof. Peter Hillemanns & Prof. Mark H. Einstein on the future role of photodynamic therapy at #IFCPC 2026. Watch: https://t.co/3CPRgxG2oG #CervicalHealth #Asieris

[AsierisPharma @asierispharma]

Prof. Marc Snijders at #IFCPC 2026 on portable, topical photodynamic therapy for cervical HSIL/CIN2/3 — a practical, non-surgical option that shortens in-clinic time and preserves cervical anatomy. Watch: https://t.co/tTYQfT7ono #CervicalHealth #Asieris

[AsierisPharma @asierispharma]

At #IFCPC 2026, Prof. Elena Ratner (Yale) on managing cervical HSIL/CIN2/3 — balancing disease control, quality of life, fertility, and non-invasive options that may aid lesion regression & HPV clearance. Watch: https://t.co/YFqQFXDIJN #CervicalHealth #Asieris

[AsierisPharma @asierispharma]

World Reproductive Health Day: Cevira® — the world's first non-invasive, fertility-preserving therapy for CIN2 cervical precancer — is now in 42 hospitals across 26 cities in China. Outpatient, no surgery. https://t.co/PLO5IVAOUk #Asieris #Cevira #WomensHealth

[AsierisPharma @asierispharma]

Cevira® — the world's first non-invasive therapy for CIN2 cervical precancerous lesions — completes its first import shipment in China. First global prescription issued in Beijing the same day.
https://t.co/d9U9ammQ4B
#Asieris #Cevira #WomensHealth #Oncology #HealthyChina

[AsierisPharma @asierispharma]

Asieris releases 2025 Annual Report: Revenue up 37.5% to RMB 277M. Flagship CEVIRA wins China NMPA approval -- world's first non-invasive treatment for precancerous cervical lesions.

https://t.co/sWvOkWZSQO

#Asieris #Cevira #WomensHealth #Pharma #Oncology #HealthyChina

[AsierisPharma @asierispharma]

Cevira endorsed with Level 1A evidence in expert consensus, setting a new benchmark for non-invasive treatment of cervical precancerous lesions. Learn more: https://t.co/CrvOJ8qsKt #Asieris #Cevira #CervicalHealth #WomensHealth #Pharma #HealthyChina

[AsierisPharma @asierispharma]

Exciting news! We've partnered with SPH Kyuan Trade (Shanghai Pharma) to bring Cevira - the world's first non-surgical treatment for precancerous cervical lesions - to China.

https://t.co/0Ku7ELajNf

#Asieris #Cevira #CervicalHealth #WomensHealth #Pharma #HealthyChina

[AsierisPharma @asierispharma]

🚨 BREAKING: Asieris receives NMPA approval for CEVIRA® (APL-1702), the world's FIRST non-invasive therapy for cervical precancerous lesions! 🧬

A game-changer for women’s health, offering a 10-min non-surgical alternative.

Details: https://t.co/SFE1t6WIhx

#Asieris #HealthTech

[AsierisPharma @asierispharma]

🚀 Exciting News! The EMA has accepted the Marketing Authorization Application for APL-1702 (Cevira®), our first-in-class non-surgical treatment for HSIL. We're one step closer to bringing this transformative therapy to women across Europe. 🌍💊Read more https://t.co/RtJZZ2ATwm

[AsierisPharma @asierispharma]

Big news! Asieris gets approval in Australia for Phase I study of APL-2401 in FGFR2/3-driven advanced solid tumors. Proud to advance cancer research! Details: https://t.co/PLmdeKvTl0
#Oncology #CancerResearch #FGFR #ClinicalTrials #Asieris

[AsierisPharma @asierispharma]

Asieris’ APL-1202 is now approved by Health Canada’s Special Access Program for free-living amoeba infections—a big step for rare disease treatment! Details: https://t.co/7aoueznnxf #amoeba #RareDiseases #Healthcare #SpecialAccess #Canada #Asieris

[AsierisPharma @asierispharma]

Asieris has submitted the CE application for APLD-2304 (bladder cancer) and it's been received by BSI Group. Proud to advance cancer care and innovation. Read more: https://t.co/bRSlzxWVqz #Asieris #BladderCancer #APLD2304 #CEApplication #Innovation

[AsierisPharma @asierispharma]

🚀 We are pleased to announce the NMPA has approved the IND for APL-2401! https://t.co/k1m8RvjPz2🌟 A vital step in our clinical journey at Asieris, committed to providing innovative treatments for genitourinary tumors and women's health. #AsierisPharma #ClinicalTrials

[AsierisPharma @asierispharma]

A rare “brain-eating” amoeba infection with almost no survivors — until now.
Science, persistence, and teamwork saved a life.
Watch this documentary: https://t.co/DKayvy79jF

#Hope #Medicine #GlobalHealth

[AsierisPharma @asierispharma]

Asieris presents Phase Ib clinical data for APL-1401 at the 19th European Colorectal Congress. Proud to drive innovation in colorectal cancer research. Read more https://t.co/t5phtUvWLJ #Asieris #APL1401 #ColorectalCancer #ClinicalTrials

[AsierisPharma @asierispharma]

Big news! Asieris publishes APRICITY phase III global trial results of APL-1702 in Cell Press journal Med. Proud to advance clinical research and innovation! Read more https://t.co/M16j1c81pg #Asieris #APRICITY #APL1702 #ClinicalTrials #Innovation

[AsierisPharma @asierispharma]

Asieris Pharmaceuticals releases its 2025 Semi-Annual Report! 📈

Strong momentum & breakthrough innovation ahead. Read more: https://t.co/jcs7Ld3Mf5 #AsierisPharma #Innovation #Healthcare

[AsierisPharma @asierispharma]

Great news! Asieris' APL-1702 NDA has advanced to the 2nd round of technical review. Another step forward in innovative healthcare. Details: https://t.co/Cl3RYO2BGr